Creative Biolabs is a world-renowned service provider for antibacterial drug discovery. Based on advanced technology and years of research, Creative Biolabs offers one-stop custom services covering the entire antibacterial drug discovery process to best suit your technical, program and budget requirements. Herein, we are happy to introduce our high-quality antibacterial drug discovery service against Acinetobacter Baumannii for global clients.
Acinetobacter baumannii is a Gram-negative bacillus that is aerobic, pleomorphic and non-motile. As a pathogen, A. baumannii specifically targets moist tissues such as mucous membranes or areas of the skin that are exposed, either through accident or injury. Skin and soft tissues infected with A. baumannii initially present with a “peau d’orange” appearance (similar to the skin of an orange) followed by a sandpaper-like presentation which eventually gives way to clear vesicles on the skin. In areas of skin disruption, hemorrhagic bullae can be seen, with a visible necrotizing process followed by bacteremia. If left untreated, this infection can lead to septicemia and death.
Fig.1 Immune response to Acinetobacter baumanniiinfection. (García-Patiño, 2017)
In recent years, A. baumannii has been designated as a “red alert” human pathogen, generating alarm among the medical fraternity, arising largely from its extensive antibiotic resistance spectrum. Currently, certain strains of A. baumannii have been identified with high resistance to most antibiotics available in clinical practice. Several resistance mechanisms to many classes of antibiotics are known to exist in A. baumannii, including β-lactamases, multidrug efflux pumps, aminoglycoside-modifying enzymes, permeability defects, and the alteration of target sites. Most of these resistance mechanisms can target different classes of antibiotics. Moreover, several different mechanisms can work together to contribute to the resistance to a single class of antibiotics.
Fig.2 Schematic representation of A. baumannii colistin resistance mechanisms. (Trebosc, 2019)
Studies have demonstrated that increasing antimicrobial resistance, especially multidrug resistance, has become a major issue in A. baumannii strains in recent years. Therefore, it is urgent to develop new antibiotics against multidrug-resistant A. baumannii (MDRAB) to aid in controlling the increasing problem of A. baumannii infections. However, new antibiotic drug development is a time-consuming process. Creative Biolabs has established advanced technology platforms that enable us to offer comprehensive antibiotic drug development services to help our clients go through the steps of target selection, lead discovery and optimization, as well as preclinical development. Our experienced scientists will give professional advice on new antibiotic drug target identification and validation.
Creative Biolabs is committed to providing the most professional antibiotic drug discovery service for the treatment of bacterial infections. For more detailed information, please feel free to contact us.
References
For Research Use Only.
